Pharmaceutical Executive-08-01-2018

Examining the rise and reach of biopharma in the key Northeast Corridor clusters of Boston, Philadelphia, and New Jersey.

Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.

With increasing responsibilities and decision-making post-discovery, the traditional label of “biotech” is changing.

New trends report spotlights the promise and cautions for prospective life sciences dealmakers.

Recent bipartisan efforts look to expand access for addiction treatment and stem inappropriate drug prescribing.

Though challenges in space and affordability remain, New York City is emerging as a hotspot for biotech incubators, including one unique startup based in the city’s fast-growing innovation center, whose CEO, like many C-suite veterans, made the career leap from the big pharma world to forging new discoveries in medical science.

Commercial leaders can boost product launches with a data-driven roadmap.

Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.

Using AI to revolutionize research inefficiency. 

European drug innovators ready their defense as the Commission mulls manufacturing waiver for generic competitors.

A common takeaway in our exploration of "Emerging Biopharma" appears to be that these companies are those that go beyond pure discovery-and put equal efforts into the pivot to potential commercialization.

Behind an economic revival in Portugal, including healthcare spending growth, the nation’s life sciences sector is benefiting as well, with Portugal diverging from the European averages to show an increase in R&D and innovation.

Click the title above to open the Pharmaceutical Executive August 2018 issue in an interactive PDF format.